- Home
- TRU vs ROIV Comparison
TRU vs ROIV Comparison
Compare TRU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | ROIV |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 14.1B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRU | ROIV |
|---|---|---|
| Price | $83.94 | $21.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $104.45 | $21.94 |
| AVG Volume (30 Days) | 1.6M | ★ 6.7M |
| Earning Date | 10-23-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ 87.22 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,441,800,000.00 | $20,329,000.00 |
| Revenue This Year | $9.59 | N/A |
| Revenue Next Year | $7.57 | $376.94 |
| P/E Ratio | $39.57 | ★ N/A |
| Revenue Growth | ★ 8.30 | N/A |
| 52 Week Low | $66.38 | $8.73 |
| 52 Week High | $101.42 | $22.45 |
Technical Indicators
Market Signals| Indicator | TRU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 65.78 |
| Support Level | $81.05 | $20.14 |
| Resistance Level | $86.61 | $21.48 |
| Average True Range (ATR) | 2.01 | 0.69 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 56.99 | 76.35 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.